within Pharmacolibrary.Drugs.ATC.A;

model A06AH04_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.37,
    Cl             = 22.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Naloxone is an opioid antagonist used primarily to rapidly reverse opioid overdose. It binds to opioid receptors and can reverse and block the effects of other opioids, including respiratory depression, sedation, and hypotension. Naloxone is approved and widely used today both in emergency settings and by bystanders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after intramuscular administration.</p><h4>References</h4><ol><li><p>Saari, TI, et al., &amp; Dale, O (2024). Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. <i>Clinical pharmacokinetics</i> 63(4) 397–422. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01355-6&quot;>10.1007/s40262-024-01355-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38485851/&quot;>https://pubmed.ncbi.nlm.nih.gov/38485851</a></p></li><li><p>Tsekouras, AA, &amp; Macheras, P (2023). Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept. <i>European journal of drug metabolism and pharmacokinetics</i> 48(4) 455–462. DOI:<a href=&quot;https://doi.org/10.1007/s13318-023-00831-x&quot;>10.1007/s13318-023-00831-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37266859/&quot;>https://pubmed.ncbi.nlm.nih.gov/37266859</a></p></li><li><p>Barr, CA, et al., &amp; Otto, CM (2023). Pharmacokinetics and pharmacodynamics of intranasal and intramuscular administration of naloxone in working dogs administered fentanyl. <i>Journal of veterinary internal medicine</i> 37(6) 2422–2428. DOI:<a href=&quot;https://doi.org/10.1111/jvim.16901&quot;>10.1111/jvim.16901</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37861360/&quot;>https://pubmed.ncbi.nlm.nih.gov/37861360</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A06AH04_1;
